Tesamorelin 5mg
£ 109.00
Tesamorelin supports fat loss and metabolic health by stimulating natural growth hormone production. It is especially effective for abdominal fat reduction.
Tesamorelin is a synthetic peptide that stimulates the release of natural growth hormone by mimicking GHRH (Growth Hormone-Releasing Hormone). Delivered in an easy-to-use nasal spray, this 15mg formulation helps reduce visceral fat, improve muscle tone, and enhance metabolic function.
Clinical studies have also shown Tesamorelin may support cognitive health and reduce inflammation, making it popular in anti-aging and body recomposition protocols.
Key Clinical Benefits:
- Promotes natural GH and IGF-1 production
- Reduces visceral (abdominal) fat
- Enhances lean muscle definition
- Supports cognitive clarity and brain health
1. Falutz J, et al. (2007)
Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. This pivotal Phase III randomized controlled trial demonstrated that tesamorelin significantly reduced visceral adipose tissue while maintaining a favorable safety profile.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/18057338/
DOI:
https://doi.org/10.1056/NEJMoa064066
2. Falutz J, et al. (2008)
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. An extension study evaluating long term efficacy and safety over 52 weeks.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/18690162/
DOI:
https://doi.org/10.1097/QAD.0b013e32830b3e4d
3. Stanley TL, et al. (2014)
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. Published in JAMA, this study found that tesamorelin reduced both visceral adipose tissue and liver fat in people with HIV.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/25038357/
DOI:
https://doi.org/10.1001/jama.2014.8334
4. Grunfeld C, et al. (2011)
Tesamorelin.
A concise review published in Nature Reviews Drug Discovery discussing the mechanism of action, approval, and clinical development of tesamorelin.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/21283099/
DOI:
https://doi.org/10.1038/nrd3362
5. Clinical Review Report (CADTH)
A comprehensive review of the Phase III clinical trials, efficacy, safety, and regulatory assessment.
You Might also like
Shop The Look
